These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 31556584)

  • 1. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative Breast Cancer.
    Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-targeted pH/redox dual-sensitive unimolecular nanoparticles for efficient siRNA delivery.
    Chen G; Wang Y; Xie R; Gong S
    J Control Release; 2017 Aug; 259():105-114. PubMed ID: 28159516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. uPAR enhances malignant potential of triple-negative breast cancer by directly interacting with uPA and IGF1R.
    Huber MC; Mall R; Braselmann H; Feuchtinger A; Molatore S; Lindner K; Walch A; Gross E; Schmitt M; Falkenberg N; Aubele M
    BMC Cancer; 2016 Aug; 16():615. PubMed ID: 27502396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple-Layered pH-Responsive Micelleplexes Loaded with siRNA and Cisplatin Prodrug for NF-Kappa B Targeted Treatment of Metastatic Breast Cancer.
    Yu H; Guo C; Feng B; Liu J; Chen X; Wang D; Teng L; Li Y; Yin Q; Zhang Z; Li Y
    Theranostics; 2016; 6(1):14-27. PubMed ID: 26722370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A uPAR targeted nanoplatform with an NIR laser-responsive drug release property for tri-modal imaging and synergistic photothermal-chemotherapy of triple-negative breast cancer.
    Yu S; Huang G; Yuan R; Chen T
    Biomater Sci; 2020 Jan; 8(2):720-738. PubMed ID: 31777866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precisely Assembled Nanoparticles against Cisplatin Resistance via Cancer-Specific Targeting of Mitochondria and Imaging-Guided Chemo-Photothermal Therapy.
    Yang GG; Pan ZY; Zhang DY; Cao Q; Ji LN; Mao ZW
    ACS Appl Mater Interfaces; 2020 Sep; 12(39):43444-43455. PubMed ID: 32883070
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.
    Mio C; Gerratana L; Bolis M; Caponnetto F; Zanello A; Barbina M; Di Loreto C; Garattini E; Damante G; Puglisi F
    Int J Cancer; 2019 Feb; 144(4):755-766. PubMed ID: 30259975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stimuli-Responsive Polymer-Prodrug Hybrid Nanoplatform for Multistage siRNA Delivery and Combination Cancer Therapy.
    Saw PE; Yao H; Lin C; Tao W; Farokhzad OC; Xu X
    Nano Lett; 2019 Sep; 19(9):5967-5974. PubMed ID: 31381852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A DNA damage nanoamplifier for the chemotherapy of triple-negative breast cancer via DNA damage induction and repair blocking.
    Huang Y; Dai X; Guan Z; Liu D; Ren L; Chen M; Zeng Z; Jiang J; Luo Y; He Y; Huang M; Zhao C
    Int J Pharm; 2022 Jun; 622():121897. PubMed ID: 35690308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
    Song Y; Tang C; Yin C
    Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1-mutated and PTEN-wild-type triple-negative breast cancer cells.
    El Guerrab A; Bamdad M; Bignon YJ; Penault-Llorca F; Aubel C
    Mol Carcinog; 2017 May; 56(5):1383-1394. PubMed ID: 27864890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyr61 and YB-1 are novel interacting partners of uPAR and elevate the malignancy of triple-negative breast cancer.
    Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
    Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer.
    Li C; Li T; Huang L; Yang M; Zhu G
    Chem Asian J; 2019 May; 14(9):1570-1576. PubMed ID: 30843348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung cancer therapy using doxorubicin and curcumin combination: Targeted prodrug based, pH sensitive nanomedicine.
    Hong Y; Che S; Hui B; Yang Y; Wang X; Zhang X; Qiang Y; Ma H
    Biomed Pharmacother; 2019 Apr; 112():108614. PubMed ID: 30798129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
    Zhou Y; Yu S; Chen D; Li H; Xu P; Yuan C; Jiang L; Huang M
    Mol Pharm; 2023 Feb; 20(2):905-917. PubMed ID: 36463525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. β-Catenin and NF-κB cooperate to regulate the uPA/uPAR system in cancer cells.
    Moreau M; Mourah S; Dosquet C
    Int J Cancer; 2011 Mar; 128(6):1280-92. PubMed ID: 20473943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance.
    Lin YX; Wang Y; An HW; Qi B; Wang J; Wang L; Shi J; Mei L; Wang H
    Nano Lett; 2019 May; 19(5):2968-2978. PubMed ID: 30924343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
    Blanchard Z; Paul BT; Craft B; ElShamy WM
    Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The targetable nanoparticle BAF312@cRGD-CaP-NP represses tumor growth and angiogenesis by downregulating the S1PR1/P-STAT3/VEGFA axis in triple-negative breast cancer.
    Gong K; Jiao J; Xu C; Dong Y; Li D; He D; Zhao D; Yu J; Sun Y; Zhang W; Bai M; Duan Y
    J Nanobiotechnology; 2021 May; 19(1):165. PubMed ID: 34059068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.